Recent Advances and Molecular Pathway in Salivary Adenoid Cystic Carcinoma (Review)

Author(s): Laijun Xu, Lingzhi Li, Shouliang Zhao*, Shangfeng Liu*

Journal Name: Current Signal Transduction Therapy

Volume 15 , Issue 2 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Salivary Adenoid Cystic Carcinoma (ACC) is a malignant tumor located at oral and maxillofacial regions, and its conventional treatments are surgery, chemotherapy and radiotherapy. However, its poor survival rates and prognosis resulting from the molecular mechanisms underlying the carcinogenesis remain obscure. To date, there are insufficient reviews to summarize the genes and molecular pathways for ACC. Therefore, it is required for us to highlight the main oncogenes, tumor suppressor genes and genetic signal transduction pathways associated with ACC in this review.

Materials and Methods: A literature review based on PubMed for the genetic characteristics and molecular transduction pathways for ACC was conducted. Ninety articles were selected as references using the search terms or keywords such as “genes, molecular pathways, salivary adenoid cystic carcinoma or ACC”.

Results: We have briefly described histopathology, current treatments and main clinical features in ACC. Besides, we have also elaborated the associated genes and pathways in this review according to the searched articles in recent years.

Conclusion: We have summarized vital genes and proteins targeting or mechanism-based on proliferation, apoptosis, invasion and metastasis. Although there are few kinds of research on ACC currently exist, we expect that better detailed genetic studies would pave the way for promising advancement in our understanding of the molecular biology and pathogenesis mechanisms underlying tumors.

Keywords: Salivary adenoid cystic carcinoma, targeted therapy, molecular pathway, vital genes, pathogenesis mechanisms, tumors.

[1]
Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivaryorigin. Am J Surg 1997; 01174(5): 495-98.
[2]
Ellington CL, Goodman M, Kono SA, Grist W, Wadsworth T, Chen AY. Adenoid cystic carcinoma of the head and neck: incidence and survival trends based on 1973-2007 surveillance, epidemiology and end results data. Cancer-Am Cancer Soc 2012; 15118(8): 4444-51.
[3]
Kaira K, Toyoda M, Shino M, et al. Clinicopathological significance of L-type amino acidtransporter 1 (LAT1) expression in patients with adenoid cystic carcinoma. Pathol Oncol Res 2013; 0119(4): 649-56.
[4]
Seethala RR. An update on grading of salivary gland carcinomas. Head Neck Pathol 2009; 013(1): 69-77.
[http://dx.doi.org/10.1007/s12105-009-0102-9]
[5]
Fordice J, Kershaw C, El-Naggar A, Goepfert H. Adenoid cysticcarcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngology Head Neck Surg 1999; 152(2): 149-52.
[http://dx.doi.org/10.1001/archotol.125.2.149]
[6]
Bradley PJ. Adenoid cystic carcinoma evaluation and management: progress with optimism. Curr Opin Otolaryngol 2017; 0125(2): 147-53.
[7]
Papaspyrou G, Hoch S, Rinaldo A, et al. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: A review. Head Neck 2011; 0133(6): 905-11.
[8]
Liu XY, Liu ZJ, He H, Zhang C, Wang YL. MicroRNA-101-3psuppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-.1. Am J Cancer Res 2015; 5(10): 3015-29.
[9]
Zhu X, Xu JJ, Hu SS, et al. Pim-1 acts as an oncogene in human salivary gland adenoid cystic carcinoma. J Exp Clin Cancer Res 2014; 33(1): 114.
[http://dx.doi.org/10.1186/s13046-014-0114-5] [PMID: 25551195]
[10]
Zhou B, Li T, Liu Y, Zhu N. Preliminary study on XAGE-1b gene and its mechanism for promoting tumor cell growth. Biomed Rep 2013; 1(4): 567-72.
[11]
Xiao C, Pan Y, Zeng X, et al. Down regulation of hypoxia inducible factor-1alpha inhibits growth, invasion and angiogenesis of human salivary adenoid cystic carcinoma cells under hypoxia. Oncol Rep 2018; 40(3): 1675-83.
[12]
Li Z, Tang P, Xu Z. Clinico-pathological significance of micro vessel density and vascular endothelial growth factor expression in adenoid cystic carcinoma of salivary glands. Chinese J Stomat 2001; 36(3): 212-4.
[13]
Kondo S, Mukudai Y, Soga D, Nishida T, Takigawa M, Shirota T. Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic. Int J Can Res Treat 2014; 34(2): 671-7.
[14]
Ou YK, Liang J, Yang ZN, Zhao JJ. A study on the inhibition of VEGF expression in salivary gland adenoid cystic carcinoma cells via iNOS gene RNAi in vitro. J Oral Pathol Med 2015; 44(2): 153-8.
[15]
Liu X, Wu H, Huang P, Zhang F. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways. J Oral Pathol Med 2018; 48(1): 43-51.
[16]
Bell D, Roberts D, Kies M, Rao P, Weber RS, El-Naggar AK. Cell type-dependent biomarker expression in adenoid cystic carcinoma: biologic and therapeutic implications. Cancer Am Cancer Soc 2010; 116(24): 5749-56.
[http://dx.doi.org/10.1002/cncr.25541]
[17]
Wang Y, Hu J, Wang Y, et al. EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 inhuman salivary adenoid cystic carcinoma cells. Cell Cycle 2018; 17(12): 1457-70.
[18]
Wen X, Lin HH, Ann DK. Salivary cellular signaling and gene regulation. Adv Dent Res 2000; 14: 76-80.
[http://dx.doi.org/10.1177/08959374000140011201]
[19]
Hu B, Xiong Y, Ni R, et al. The down regulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma. Mol Cell Biochem 2014; 396(1-2): 175-85.
[20]
Sun J, Luo Y, Tian Z, Gu L, Xia SC, Yu Y. Expression of ERBB3binding protein 1 (EBP1) in salivary adenoid cystic carcinoma and its clinic pathological relevance. BMC Cancer 12: 499.
[21]
Qiu CW, Liu ZY, Hou K, et al. Wip1 knockout inhibits neurogenesis by affecting the Wnt/beta-catenin signaling pathway in focal cerebral ischemia in mice. Exp Neurol 2018; 309: 44-53.
[22]
Peng TS, He YH, Nie T, et al. PPM1D is prognostic marker and therapeutic target in colorectal cancer. Exp Ther Med 2014; 8(2): 430-4.
[23]
Tang YL, Liu X, Gao SY, et al. WIP1 stimulates migration and invasion of salivary adenoid cystic carcinoma by inducing MMP-9 and VEGF-C. Onco-Target 2015; 6(11): 9031-44.
[24]
Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa] B activity. Annu Rev Immunol 2000; 18: 621-63.
[25]
Xu D, Li D, Lu Z, Dong X, Wang X. Type III TGF-beta receptor inhibits cell proliferation and migration in salivary glands adenoid cystic carcinoma by suppressing NF-kappa B signaling. Oncol Rep 2016; 35(1): 267-74.
[26]
Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor kappa B in pancreatic cancer metastasis. Clin Cancer Res 2003; 9(1): 346-54.
[27]
Zhang J, Peng B, Chen X. Expressions of nuclear factor kappa inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res 2005; 11(20): 7334-43.
[28]
Liu Z, Huang S, Zhang S, et al. Suppression of NF-kappaB activity by mutant I kappa B alpha: A molecular target for radio sensitization of adenoid cystic carcinoma. Oncol Lett 2013; 5(4): 1375-81.
[29]
Honma K, Miyata T, Ochiya T. Type I collagen gene suppresses tumor growth and invasion of malignant human glioma cells. Cancer Cell Int 2007; 7: 12.
[30]
Freitas VM, Vilas-Boas VF, Pimenta DC, et al. SIKVAV, a laminin alpha1-derived peptide, interacts with integrin’s and increases protease activity of a human salivary gland adenoid cystic carcinoma cell line through the ERK1/2 signaling pathway. Am J Pathol 2007; 171(1): 124-38.
[31]
Sun J, Yu YC, Luo YX, Tian Z. Expression of erythroblast leukemia viral oncogene homo-log 3 (ErbB-3) binding protein-1, matrix metalloproteinases, epithelial cadherin in adenoid cystic carcinoma and correlation analysis. Chinese J Stomat 2012; 47(12): 711-14.
[32]
Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005; 5(3): 231-7.
[http://dx.doi.org/10.1038/nrc1560]
[33]
Nakahara T, Kita A, Yamanaka K, et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67(17): 8014-21.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-1343]
[34]
Wang YF, Zhang W, He KF, et al. Induction of autophagydependent cell death by the survivin suppressantYM155 in salivary adenoid cystic carcinoma. Apoptosis 2014; 19(4): 748-58.
[http://dx.doi.org/10.1007/s10495-013-0960-1.]
[35]
Wang Y, Ma S, Wang W, et al. Inhibition of survivin reduces hif-1α, tgf-β1 and tfe3 in salivary adenoid cystic carcinoma. PLoS ONE 2014; 9(12): e114051.
[36]
Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr Mol 2006; 6(1): 45-54.
[37]
Kaira K, Toyoda M, Shimizu A, et al. Expression of ER stress markers (GRP78/BiP and PERK) in adenoid cystic carcinoma. Acta Otolaryngol 2016; 136(1): 1-7.
[38]
Chiarle R, Fan Y, Piva R, et al. S-phase kinase-associated protein 2 expression in non-Hodgkin lymphoma inversely correlates with p27 expression and defines cells in S phase. Am J Pathol 2002; 160(4): 1457-66.
[39]
Keikhaee MR, Kudo Y, Siriwardena S, Wu L, Ogawa I, Takata T. Skp 2 expression is associated with down-regulation of p27 protein and cell proliferation in salivary adenoid cystic carcinoma. Virchows Arch 2007; 450(5): 567-74.
[http://dx.doi.org/10.1007/s00428-007-0391-x]
[40]
Zhang H, Kobayashi R, Galaktionov K, Beach D. p19Skp1 andp45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 1995; 82(6): 915-25.
[41]
Darnell JJ. STATs and gene regulation. Science 1997; 277(5332): 1630-35.
[http://dx.doi.org/10.1126/science.277.5332.1630]
[42]
Galoczova M, Coates P, Vojtesek B. STAT3, stem cells, cancer stem cells and p63. Cell Mol Biol Lett 2018; 23: 12.
[http://dx.doi.org/10.1186/s11658-018-0078-0]
[43]
Bu LL, Deng WW, Huang CF, Liu B, Zhang WF, Sun ZJ. Inhibition of STAT3 reduces proliferation and invasion in salivary gland adenoid cystic carcinoma. Am J Cancer Res 2015; 5(5): 1751-61.
[44]
Yu GT, Bu LL, Zhao YY, et al. Inhibition of mTOR reduce Stat3 and PAI related angiogenesis in salivary gland adenoid cystic carcinoma. Am J Cancer Res 2014; 4(6): 764-75.
[45]
Fan TF, Deng WW, Bu LL, Wu TF, Zhang WF, Sun ZJ. B7-H3regulates migration and invasion in salivary gland adenoid cystic carcinoma via the JAK2/STAT3 signaling pathway. Am J Transl Res 2017; 9(3): 1369-80.
[46]
Lin L, Amin R, Galliano GI, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGFbeta signaling. Oncogene 2009; 28(7): 961-72.
[47]
Li W, Zou ST, Zhu R, Wan JM, Xu Y, Wu HR. B cell translocation1 gene inhibits cellular metastasis associated behavior in breast cancer. Mol Med Rep 2014; 9(6): 2374-80.
[48]
Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009; 15(1): 59-67.
[49]
Li H, Liao X, Liu Y, et al. The expression of MACC1 and its role in the proliferation and apoptosis of salivary adenoid cystic carcinoma. J Oral Pathol Med 2015; 44(10): 810-17.
[50]
Fetsch PA, Abati A, Litman T, et al. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett 2006; 235(1): 84-92.
[51]
Li W, Tamamura R, Wang B, et al. Expressions of ABCG2, CD133, and podoplanin in salivary adenoid cystic carcinoma. BioMed Res Int 2014; 2014: 1-11.
[52]
Heldin CH. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal 2013; 11: 97.
[http://dx.doi.org/10.1186/1478-811X-11-97]
[53]
Kazlauskas A. PDGFs and their receptors. Gene 2017; 614: 1-7.
[http://dx.doi.org/10.1016/j.gene.2017.03.003]
[54]
Perrone F, Da RL, Orsenigo M, et al. PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. NeuroOncol 2009; 11(6): 725-73.
[55]
Koo JS, Park S, Kim SI, Lee S, Park BW. The impact of caveolin protein expression in tumor stroma on prognosis of breast cancer. Tumour Biol 2011; 32(4): 787-99.
[http://dx.doi.org/10.1007/s13277-011-0181-6]
[56]
Vekony H, Ylstra B, Wilting SM, et al. DNA copy number gains at loci of growth factors and their receptors in salivary gland adenoid cystic carcinoma. Clin Cancer Res 2007; 13(11): 3133-9.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-2555]
[57]
Ramer N, Wu H, Sabo E, et al. Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysis. Cancer Am Soc 2009; 116(1): 77-83.
[58]
Ramer N, Wu H, Sabo E, et al. Prognostic value of quantitative p63 immunostaining in adenoid cystic carcinoma of salivary gland assessed by computerized image analysis. Cancer Am Soc 2010; 116(1): 77-83.
[59]
Ho AS, Kannan K, Roy DM, et al. The mutational landscape of adenoid cystic carcinoma. Nat Gene 2013; 45(7): 791-8.
[http://dx.doi.org/10.1038/ng.2643]
[60]
Bell D, Roberts D, Karpowicz M, Hanna EY, Weber RS, El-Naggar AK. Clinical significance of MYB protein and downstream target genes in salivary adenoid cystic carcinoma. Cancer Biol Ther 2011; 12(7): 569-73.
[http://dx.doi.org/10.4161/cbt.12.7.17008]
[61]
Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genesis carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 2009; 106(44): 18740-44.
[http://dx.doi.org/10.1073/pnas.0909114106]
[62]
Mitani Y, Li J, Rao PH, et al. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinic pathologic significance. Clin Cancer Res 2010; 16(19): 4722-31.
[63]
Ono J, Okada Y. Study of MYB-NFIB chimeric gene expression, tumor angiogenesis, and proliferation in adenoid cystic carcinoma of salivary gland. Odontol 2018; 106(3): 238-44.
[http://dx.doi.org/10.1007/s10266-017-0326-1]
[64]
Xie M, Wei S, Wu X, Li X, You Y, He C. Alterations of notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival. Lung Cancer 2018; 121: 41-7.
[http://dx.doi.org/10.1016/j.lungcan.2018.04.020]
[65]
Ntziachristos P, Lim JS, Sage J, Aifantis I. From fly wings to targeted cancer therapies: A centennial for notch signaling. Cancer Cell 2014; 25(3): 318-34.
[http://dx.doi.org/10.1016/j.ccr.2014.02.018]
[66]
Ding LC, She L, Zheng DL, et al. Notch-4 contributes to the metastasis of salivary adenoid cystic carcinoma. Oncol Rep 2010; 24(2): 363-8.
[67]
Grigorian A, Hurford R, Chao Y, Patrick C, Langford TD. Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir. BMC Neurosci 2008; 9: 27.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-2208]
[68]
Panaccione A, Chang MT, Carbone BE, et al. NOTCH1 and SOX10 are essential for proliferation and radiation resistance of cancer stem-like cells in adenoid cystic carcinoma. Clin Cancer Res 2016; 22(8): 2083-95.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-2208]
[69]
Sherwood V. WNT signaling: an emerging mediator of cancer cell metabolism? Mol Cell Biol 2015; 35(1): 2-10.
[http://dx.doi.org/10.1128/MCB.00992-14]
[70]
Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta catenin signaling: diseases and therapies. Nat Rev Genet 2004; 5(9): 691-701.
[71]
Wang R, Geng N, Zhou Y, et al. Aberrant Wnt-1/beta-catenin signaling and WIF-1 deficiency are important events which promote tumor cell invasion and metastasis in salivary gland adenoid cystic carcinoma. Biomed Mater Eng 2015; 26(Suppl 1): S2145-53.
[72]
Wendt MK, Tian M, Schiemann WP. Deconstructing the mechanisms and consequences of TGF-beta-induced EMT during cancer progression. Cell Tissue Res 2012; 347(1): 85-101.
[73]
Dong L, Wang YX, Li SL, et al. TGF beta1 promotes migration and invasion of salivary adenoid cystic carcinoma. J Dent Res 2011; 90(6): 804-9.
[74]
Dong L, Ge XY, Wang YX, et al. Transforming growth factor-βand epithelial-mesenchymal transition are associated with pulmonary metastasis in adenoid cystic carcinoma. Oral Oncol 2013; 49(11): 1051-8.
[http://dx.doi.org/10.1016/j.oraloncology.2013.07.012] [PMID: 23962790]
[75]
Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133(4): 704-5.
[http://dx.doi.org/10.1016/j.cell.2008.03.027]
[76]
Wang Y, Hu J, Wang Y, et al. EGFR activation induced Snaildependent EMT and myc-dependent PD-L1 inhuman salivary adenoid cystic carcinoma cells. Cell Cycle 2018; 17(12): 1457-70.
[77]
Dong L, Ge XY, Wang YX, et al. Transforming growth factor-beta and epithelial-mesenchymal transition are associated with pulmonary metastasis in adenoid cystic carcinoma. Oral Oncol 2013; 49(11): 1051-8.
[78]
Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988; 335(6185): 88-9.
[http://dx.doi.org/10.1038/335088a0]
[79]
Omori I, Yamaguchi H, Miyake K, Miyake N, Kitano T. D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia. Exp Hematol 2017; 52: 56-64.
[80]
Dodd RL, Slevin NJ. Salivary gland adenoid cystic carcinoma: are view of chemotherapy and molecular therapies. Oral 2006; 42(8): 759-69.
[http://dx.doi.org/10.1016/j.oraloncology.2006.01.001]
[81]
Seethala RR, Barnes EL, Hunt JL. Epithelial-myoepithelial carcinoma: a review of the clinico-pathologic spectrum and immunophenotypic characteristics in 61 tumors of the salivary glands and upper aero digestive tract. Am J Surg Pathol 2007; 31(1): 44-57.
[82]
Tang YL, Fan YL, Jiang J, et al. C-kitinduces epithelialmesenchymal transition and contributes to salivary adenoid cystic cancer progression. Onco-Target 2014; 5(6): 1491-501.
[83]
Wong SJ, Karrison T, Hayes DN, et al. Phase II trial of dasatinib for recurrent or metastatic-KIT expressing adenoid cystic carcinoma and for non-adenoid cystic malignant salivary tumors. Ann Oncol 2016; 27(2): 318-23.
[http://dx.doi.org/10.1093/annonc/mdv537]
[84]
Coca-Pelaz A, Rodrigo JP, Bradley PJ, et al. Adenoid cystic carcinoma of the head and neck-An update. Oral Oncol 2015; 51(7): 652-61.
[85]
Cordesmeyer R, Schliephake H, Kauffmann P, et al. Clinical prognostic factors of salivary adenoid cystic carcinoma: A single-center analysis of 61 patients. J Cranio maxillofac Sur. 2017; 45(11): 1784-87.
[86]
He S, Li P, Zhonghu Q, et al. Clinico pathologic and prognostic factors in adenoid cystic carcinoma of head and neck minor salivary glands: a clinical analysis of 130 cases. Am J Otolaryngol 2017; 38(2): 157-62.
[http://dx.doi.org/10.1016/j.amjoto.2016.11.014]
[87]
Chae YK, Chung SY, Davis AA, et al. Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. OncoTarget 2015; 6(35): 37117-34.
[http://dx.doi.org/10.18632/oncotarget.5076]


open access plus

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 2
Year: 2020
Published on: 01 December, 2020
Page: [205 - 214]
Pages: 10
DOI: 10.2174/1574362414666190204124731

Article Metrics

PDF: 22
HTML: 2
PRC: 2